INT82845

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 25
Total Number 25
Disease Relevance 7.07
Pain Relevance 0.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (F10) extracellular region (F10) plasma membrane (F10)
Anatomy Link Frequency
platelet 10
plasma 5
plaque 1
F10 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 35 91.36 High High
cva 259 91.12 High High
Inflammation 7 78.36 Quite High
Angina 4 75.00 Quite High
aspirin 10 64.12 Quite High
Pain 6 60.48 Quite High
addiction 1 56.44 Quite High
cINOD 21 40.32 Quite Low
antagonist 44 36.24 Quite Low
Parenteral administration 1 23.36 Low Low
Disease Link Frequency Relevance Heat
Adhesions 22 99.26 Very High Very High Very High
Rupture 8 99.06 Very High Very High Very High
Thrombosis 336 98.20 Very High Very High Very High
Paralysis 1 93.64 High High
Heparin-induced Thrombocytopenia 20 92.72 High High
Atherosclerotic Plaque 4 92.32 High High
Corneal Disease 1 91.68 High High
Cv General 3 Under Development 162 91.12 High High
Necrosis 3 90.60 High High
Uveitis 1 89.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As a consequence the direct FXa inhibitors are able to inhibit both free FXa and FXa bound in the prothrombinase complex (Perzborn 2005) (Figure 1).
FXa Binding (bound) of
1) Confidence 0.37 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0.03
In vitro studies have shown that rivaroxaban can inhibit both free FXa and FXa bound in the prothrombinase complex more potently in human and rabbit plasma than in rat plasma.
FXa Binding (bound) of in plasma
2) Confidence 0.37 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.22 Pain Relevance 0.05
As a consequence the direct FXa inhibitors are able to inhibit both free FXa and FXa bound in the prothrombinase complex (Perzborn 2005) (Figure 1).
FXa Binding (bound) of
3) Confidence 0.37 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0.03
In vitro studies have shown that rivaroxaban can inhibit both free FXa and FXa bound in the prothrombinase complex more potently in human and rabbit plasma than in rat plasma.
FXa Binding (bound) of in plasma
4) Confidence 0.37 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.22 Pain Relevance 0.05
The exposure of tissue factors following the plaque rupture causes activation of coagulation cascades and formation of factor Xa.
factor Xa Binding (formation) of in plaque associated with rupture
5) Confidence 0.36 Published 2008 Journal Acta Med Indones Section Abstract Doc Link 19530369 Disease Relevance 0.90 Pain Relevance 0.07
Previously, it was demonstrated that immunoliposomes, bearing anti-intercellular adhesion molecule-1 (ICAM-1) antibodies (mAb F10.2), can specifically bind to different cell types expressing ICAM-1.
F10 Binding (bind) of associated with adhesions
6) Confidence 0.35 Published 1999 Journal Biochim. Biophys. Acta Section Abstract Doc Link 10407086 Disease Relevance 0.17 Pain Relevance 0
We next evaluated the binding of FXa, which has been shown to assemble on the platelet surface as part of the prothrombinase complex.
FXa Binding (binding) of in platelet
7) Confidence 0.33 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2861630 Disease Relevance 0.08 Pain Relevance 0
Unlike heparin, fondaparinux does not inactivate thrombin or inhibit FXa bound in the prothrombinase complex and therefore does not completely inhibit FXa.
FXa Binding (bound) of
8) Confidence 0.29 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 0.93 Pain Relevance 0.03
In vitro studies have shown that rivaroxaban can inhibit both free FXa and FXa bound in the prothrombinase complex more potently in human and rabbit plasma than in rat plasma.
prothrombinase Binding (complex) of in plasma
9) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.23 Pain Relevance 0.05
In vitro studies have shown that rivaroxaban can inhibit both free FXa and FXa bound in the prothrombinase complex more potently in human and rabbit plasma than in rat plasma.
FXa Binding (free) of in plasma
10) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.22 Pain Relevance 0.05
The prothrombinase complex is then formed on the platelet surface and incorporation of FXa into this complex increases the rate of thrombin generation tremendously.
prothrombinase Binding (complex) of in platelet
11) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.06 Pain Relevance 0
As a consequence the direct FXa inhibitors are able to inhibit both free FXa and FXa bound in the prothrombinase complex (Perzborn 2005) (Figure 1).
prothrombinase Binding (complex) of
12) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0.03
In vitro studies have shown that rivaroxaban can inhibit both free FXa and FXa bound in the prothrombinase complex more potently in human and rabbit plasma than in rat plasma.
FXa Binding (free) of in plasma
13) Confidence 0.29 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0.22 Pain Relevance 0.05
OG488-FXa binding was restricted to small structures, resulting in a fluorescence surface area coverage of 9.6±1.2% (Fig. 3B).
FXa Binding (binding) of
14) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2861630 Disease Relevance 0.07 Pain Relevance 0
Video images were recorded following injection of OG488-labeled fibrinogen, prothrombin, FXa or anti-CD41 (integrin ?
FXa Binding (fibrinogen) of
15) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2861630 Disease Relevance 0.29 Pain Relevance 0
In parallel with our in vitro studies, a punctate distribution of FXa was observed, in accord with the notion that FXa binding is localized to the platelet surface during thrombus formation.
FXa Binding (binding) of in platelet associated with thrombosis
16) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2861630 Disease Relevance 0.39 Pain Relevance 0
Our results point to an initial binding of prothrombin to the FXa-containing prothrombinase complex at PS-exposing platelets (thrombin formation), followed by redistribution of active thrombin to the platelet-fibrin thrombus.
prothrombinase Binding (complex) of in platelet associated with thrombosis
17) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2861630 Disease Relevance 0.23 Pain Relevance 0
At low shear, platelets demonstrated increased Ca2+ signaling and PS exposure, and supported binding of FXa and prothrombin.
FXa Binding (binding) of in platelets
18) Confidence 0.25 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2861630 Disease Relevance 0.23 Pain Relevance 0
On the contrary, direct FXa inhibitors, including rivaroxaban, do not need AT to exert their inhibitory action on FXa, because they are able to bind directly to the active site of FXa, thereby preventing interaction with its substrates.
FXa Binding (bind) of
19) Confidence 0.24 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597756 Disease Relevance 0 Pain Relevance 0.03
Thrombi formed in vivo consisted of platelet aggregates, focal spots of platelets binding FXa, and large areas binding (pro)thrombin and fibrin(ogen).


FXa Binding (binding) of in platelets
20) Confidence 0.21 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2861630 Disease Relevance 0.27 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox